一、 个人简介

吴云皓，山东第一医科大学副教授，博士生导师，博士后合作导师，山东省高等学校“青创团队”带头人，担任中国中西医结合学会耳鼻咽喉科专业委员会植物药研究专家委员会副主任委员，江苏省发育生物学学会听觉科学专业委员会委员，山东省研究型医院协会杰出青年学者分会委员，同时担任Current Medicinal Chemistry、现代中医药、陕西中医药大学学报等杂志编委，Frontiers in Medicine专刊编辑。研究领域：老年性耳聋的代谢调控机制及药物防治研究。近五年以第一作者/通讯作者（含共同）发表SCI期刊论文11篇（IF＞10分6篇），主持国自然面上基金、国自然青年基金、山东省自然面上基金等多个项目，申请国家发明专利4项。

二、 代表论著

1. Wu Y^#, Zhang L^#, Cao S^#, Zhang J, Li C, Shan Y, Liu Q, Yu Z, Fang Q, Zhang Y, Fu X*, So K*, Chai R*. Lycium barbarum Glycopeptide Alleviates Neomycin-induced Ototoxicity by Inhibiting Tryptophan Hydroxylase-mediated Serotonin Biosynthesis. Advanced Science. 2025; Accept. (IF=14.3)

2. Guo S^#, Cheng C^#, Wu Y^#, Shen K^#, Zhang D, Chen B, Wang X, Shen L, Zhang Q, Chai R*, Wang G*, Zhou F*. Metabolomic and Cellular Mechanisms of Drug-Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid Modulation. Advanced Science. 2025; 5: e2415041. (IF=14.3)

3. Aging Biomarker Consortium, Xiaolong Fu^#, Si Wang^#, Yunhao Wu^#, Yu Sun^#, Wenwen Liu^#, Xin Xi*, Genglin Li*, Ke Liu*, Wei Yuan*, Fangyi Chen*, Hongyang Wang*, Tao Yang*, Yuhe Liu*, Jialin Zheng*, Haibo Shi*, Jing Qu*, Xiaowei Chen*, Limin Suo*, Yideng Huang*, Xinbo Xu*, Xuxia Tang*, Lei Xu*, Xia Gao*, Li sheng Yu*, Yilai Shu*, Weiqi Zhang*, Jinpeng Sun*, Huijun Yuan*, Shusheng Gong*, Wenyan Li*, Xiulan Ma*, Dingjun Zha*, Jiangang Gao*, Huawei Li*, Zuhong He*, Guang-Hui Liu*, Gang Pei*, Weijia Kong*, Haibo Wang*, Renjie Chai*. A biomarker framework for auditory system aging: the Aging Biomarker Consortium consensus statement. Life Medicine. 2025; lnaf011, https://doi.org/10.1093/lifemedi/lnaf011.

4. Guo Z^#, Wu Y^#, Chen B, Kong M, Xie P, Li Y, Liu D*, Chai R*, Gu N*. Superparamagnetic iron oxide nanoparticle regulates microbiota-gut-inner ear axis for hearing protection. National Science Review. 2024; 11(6): nwae100. (IF=16.3)

5. Wu Y^#*, Zhang J^#, Liu Q, Miao Z, Chai R*, Chen W*. Development of Chinese herbal medicine for sensorineural hearing loss. Acta Pharm Sin B. 2024; 14(2):455-467. (IF=14.7)

6. Wu Y^#, Yu X^#, Wang Y, Huang Y, Tang J, Gong S, Jiang S, Xia Y, Li F, Yu B, Zhang Y*, Kou J*. Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling. Acta Pharm Sin B. 2022; 12(3):1198-1212. (IF=14.5)

7. Chen B^#, Cheng C^#, Wu Y^#, Li S^#, Han M, Zhen L, Peng Y, Guo S, Shen K, Gao X, Chai R*, Wang G*, Zhou F*. PGC-1α-mediated imbalance of mitochondria-lipid droplet homeostasis in neomycin-induced ototoxicity and nephrotoxicity. Acta Pharm Sin B. 2024; 14(10):4413-4430. (IF=14.7）

8. Wang Y^#, Wu Y^#, Zhang J, Tang J, Fan R, Li F, Yu B, Kou J^*, Zhang Y^*. Ruscogenin attenuates particulate matter-induced acute lung injury in mice via protecting pulmonary endothelial barrier and inhibiting TLR4 signaling pathway. Acta Pharmacol Sin. 2021; 42(5):726-734. (IF=7.16)

9. Wu Y^#, Wang Y^#, Gong S, Tang J, Zhang J, Li F, Yu B, Zhang Y^*, Kou J^*. Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by suppressing TLR4 signaling. Biomed Pharmacother. 2020; 125:109868. (IF=6.53)

10. Zhang Q^#, Wu Y^#*, Yu Y^#, Niu Y^#, Fang Q, Chen X, Qi J, Zhang C, Wu G^*, Su K^*, Chai R^*. Tetrandrine Prevents Neomycin-Induced Ototoxicity by Promoting Steroid Biosynthesis. Front Bioeng Biotechnol. 2022; 10:876237. (IF=5.69)

三、招生要求

学术型：偏向药理学研究、分子代谢研究、耳聋研究等方向

专业型：偏向耳鼻咽喉科学、分子生物学研究、药学研究方向